| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics |
PAR-25-070 (R21 Clinical Trial Not Allowed) |
R21 |
Clinical Trial Not Allowed |
01/07/2027 |
Edward Sauter, M.D., Ph.D. |
| Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics |
PAR-25-069 (R01 Clinical Trial Optional) |
R01 |
Clinical Trial Optional |
01/07/2027 |
Edward Sauter, M.D., Ph.D. |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery |
PAR-25-043 (R01 Clinical Trial Optional) |
R01 |
Clinical Trial Optional |
01/07/2028 |
Edward Sauter, M.D., Ph.D. |
| Mechanisms that Impact Cancer Risk after Bariatric Surgery |
PAR-25-044 (R21 Clinical Trial Not Allowed) |
R21 |
Clinical Trial Not Allowed |
01/07/2028 |
Edward Sauter, M.D., Ph.D. |
| HEAL Initiative: Studies to Enable Analgesic Discovery |
RFA-NS-25-023 (R61/R33 - Clinical Trial Not Allowed) |
R61, R33 |
Clinical Trial Not Allowed |
02/20/2027 |
Rachel Altshuler, Ph.D. |
| Enhancing Mechanistic Research on Precision Probiotic Therapies |
PAR-25-211 (R61/R33 Clinical Trial Optional) |
R61, R33 |
Clinical Trial Optional |
06/02/2027 |
Gabriela Riscuta, M.D., CNS |
| Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies |
PAR-25-145 (R01 Clinical Trial Optional) |
R01 |
Clinical Trial Optional |
01/07/2028 |
Rachel Altshuler, Ph.D. |
| Cancer Prevention and Control Clinical Trials Planning Grant Program |
PAR-25-104 (R34 Clinical Trials Optional) |
R34 |
|
10/25/2027 |
Goli Samimi, Ph.D., M.P.H. |
| Cancer Prevention and Control Clinical Trials Planning Grant Program |
PAR-25-103 (U34 Clinical Trials Optional) |
U34 |
|
10/25/2027 |
Brandy Heckman-Stoddard, Ph.D., M.P.H. |
| Cancer Prevention and Control Clinical Trials Grant Program |
PAR-25-167 (R01 Clinical Trial Required) |
R01 |
Clinical Trial Required |
01/07/2027 |
Goli Samimi, Ph.D., M.P.H. |